Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Yen Lin Chia"'
Autor:
Michael Hwang, Yen Lin Chia, Yanan Zheng, Cecil Chi‐Keung Chen, Jimmy He, Xuyang Song, Diansong Zhou, Sarah B. Goldberg, Lillian L. Siu, David Planchard, Solange Peters, Helen Mann, Lee Krug, Caroline Even
Publikováno v:
British Journal of Clinical Pharmacology. 89:1601-1616
Tremelimumab, a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) human monoclonal antibody of the immunoglobulin G2 kappa isotype, has been studied in oncology clinical trials as both monotherapy and in combination with durvalumab. This study cha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dda10bf08119dfeeaa4f9ceddc34be9
https://doi.org/10.1111/bcp.15622
https://doi.org/10.1111/bcp.15622
Autor:
Yen Lin, Chia, Raj, Tummala, Tu H, Mai, Tomas, Rouse, Katie, Streicher, Wendy I, White, Eric F, Morand, Richard A, Furie
Publikováno v:
The Journal of Clinical Pharmacology. 62:1094-1105
This study aimed to elucidate the pharmacokinetic/pharmacodynamic and pharmacodynamic/efficacy relationships of anifrolumab, a type I interferon receptor antibody, in patients with moderate to severe systemic lupus erythematosus. Data were pooled fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::821efe577a03274d540e7843b56b0f14
https://doi.org/10.1002/jcph.2054
https://doi.org/10.1002/jcph.2054
Publikováno v:
Rheumatology. 61:1900-1910
Objectives To characterize the relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with moderate to severe SLE despite standard therapy, using pooled data from two phase 3 trials. Methods TULIP-1 and TULIP-2 were randomi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6a45bbb3bfb4385453be94dc83d3320
https://doi.org/10.1093/rheumatology/keab704
https://doi.org/10.1093/rheumatology/keab704
Autor:
Devra Olson, Yen Lin Chia, Enaharo Iboi, Lauren Farr, Maddy Burcher, Anthony Lee, Kelly Hensley, Sean Allred, Abbie Wong, Masashi Shimazaki, Masamichi Mori, Sharsti Sandall, Christopher Carosino
Publikováno v:
Cancer Research. 83:LB246-LB246
Enfortumab vedotin (EV) is a monomethyl auristatin E (MMAE)-containing antibody-drug conjugate directed to Nectin-4, which is highly expressed in bladder cancers. Preclinically, EV has demonstrated tumor cell killing by direct cytotoxicity and bystan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ecbc389645028849f7d4c6fea700789
https://doi.org/10.1158/1538-7445.am2023-lb246
https://doi.org/10.1158/1538-7445.am2023-lb246
Autor:
Zufei Zhang, Daping Zhang, Wenchuan Guo, Keenan Fenton, Sujata Narayanan, Shweta Jain, Joy Jiang, Sharon M. Castellino, Kara M. Kelly, Peter D. Cole, Frank G. Keller, Amit Garg, Yen Lin Chia
Publikováno v:
Cancer Research. 83:6737-6737
Introduction: High-risk cHL in pediatric patients (pts) is typically treated with chemotherapy and radiation. BV, an antibody-drug conjugate (ADC) directed to CD30, is approved in six adult indications including cHL and in children with previously un
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc2835bcd50b68b64040785004e7ec87
https://doi.org/10.1158/1538-7445.am2023-6737
https://doi.org/10.1158/1538-7445.am2023-6737
Autor:
Raj Tummala, Shiliang Wang, Lorin Roskos, Bing Wang, Linda Santiago, Denison Kuruvilla, Yen Lin Chia
Publikováno v:
Rheumatology. 60:5854-5862
Objectives The randomized, double-blind, phase 2 b MUSE study evaluated the efficacy and safety of the type I IFN receptor antibody anifrolumab (300 mg or 1000 mg every 4 weeks) compared with placebo for 52 weeks in patients with chronic, moderate to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::962edd9d56d3ed2cd033aae87af98080
https://doi.org/10.1093/rheumatology/keab176
https://doi.org/10.1093/rheumatology/keab176
Autor:
Raj Tummala, Catharina Lindholm, Ian N Bruce, Alireza Nami, Tomas Rouse, Gabriel Abreu, Yen Lin Chia, Denison Kuruvilla, M. Edward Pierson, Erik Schwetje
Publikováno v:
The Lancet Rheumatology. 3:e101-e110
Summary Background 300 mg of intravenous anifrolumab every 4 weeks added to standard-of-care treatment for patients with systemic lupus erythematosus (SLE) reduced disease activity and glucocorticoid requirement in a previous phase 3 trial. Because p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fcfca6e4934e80969dfa7c8e0fba41ba
https://doi.org/10.1016/s2665-9913(20)30342-8
https://doi.org/10.1016/s2665-9913(20)30342-8
Autor:
Joachim Almquist, Denison Kuruvilla, Tu Mai, Raj Tummala, Wendy I. White, Weifeng Tang, Lorin Roskos, Yen Lin Chia
Publikováno v:
Journal of clinical pharmacology. 62(9)
We characterized the population pharmacokinetics of anifrolumab, a type I interferon receptor-blocking antibody. Pharmacokinetic data were analyzed from the anifrolumab (intravenous [IV], every 4 weeks) arms from 5 clinical trials in patients with sy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc9a68d93ef6e428c3233f97cca0ca03
https://pubmed.ncbi.nlm.nih.gov/35383948
https://pubmed.ncbi.nlm.nih.gov/35383948
Autor:
David Jayne, Brad Rovin, Eduardo F Mysler, Richard A Furie, Frederic A Houssiau, Teodora Trasieva, Jacob Knagenhjelm, Erik Schwetje, Yen Lin Chia, Raj Tummala, Catharina Lindholm
Publikováno v:
Annals of the Rheumatic Diseases, Vol. 81, no.4, p. 496-506 (2022)
ObjectiveTo assess the efficacy and safety of the type I interferon receptor antibody, anifrolumab, in patients with active, biopsy-proven, Class III/IV lupus nephritis.MethodsThis phase II double-blinded study randomised 147 patients (1:1:1) to rece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2064784894f349f590e6e8c8a7d04df6
https://pubmed.ncbi.nlm.nih.gov/35523957
https://pubmed.ncbi.nlm.nih.gov/35523957
Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma
Publikováno v:
Clinical Pharmacology and Therapeutics
We evaluated the relationship between benralizumab (30 mg every 4 and 8 weeks (Q4W, Q8W)) pharmacokinetic (PK) exposure and end points of asthma exacerbation rates (AERs) and change from baseline in prebronchodilator forced expiratory volume in 1 sec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b42379c176f0f57a46e5767d9e5a97af
http://europepmc.org/articles/PMC6767326
http://europepmc.org/articles/PMC6767326